173 related articles for article (PubMed ID: 19134027)
1. Prevention of arthropathy in haemophilia - intensive on-demand treatment, UK perspective.
Lee CA
Haemophilia; 2008 Nov; 14 Suppl 6():11-5. PubMed ID: 19134027
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations.
Jiménez-Yuste V; Alvarez MT; Martín-Salces M; Quintana M; Rodriguez-Merchan C; Lopez-Cabarcos C; Velasco F; Hernández-Navarro F
Haemophilia; 2009 Jan; 15(1):203-9. PubMed ID: 19149850
[TBL] [Abstract][Full Text] [Related]
3. Some recent developments regarding arthropathy and inhibitors in haemophilia.
Rodriguez-Merchan EC
Haemophilia; 2008 Mar; 14(2):242-7. PubMed ID: 18201189
[TBL] [Abstract][Full Text] [Related]
4. Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor.
Steen Carlsson K; Astermark J; Donfield S; Berntorp E
Thromb Haemost; 2008 Jun; 99(6):1060-7. PubMed ID: 18521509
[TBL] [Abstract][Full Text] [Related]
5. Prevention of haemophilic arthropathy in haemophilic children with inhibitors.
Rodriguez-Merchan EC
Haemophilia; 2008 Nov; 14 Suppl 6():1-3. PubMed ID: 19134025
[TBL] [Abstract][Full Text] [Related]
6. Experiences in the prevention of arthropathy in haemophila patients with inhibitors.
Jimenez-Yuste V; Rodriguez-Merchan EC; Alvarez MT; Quintana M; Martin-Salces M; Hernandez-Navarro F
Haemophilia; 2008 Nov; 14 Suppl 6():28-35. PubMed ID: 19134031
[TBL] [Abstract][Full Text] [Related]
7. Prophylaxis in haemophilia with inhibitors: update from international experience.
Carcao M; Lambert T
Haemophilia; 2010 Mar; 16 Suppl 2():16-23. PubMed ID: 20132334
[TBL] [Abstract][Full Text] [Related]
8. Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors?
Rodriguez-Merchan EC; Hedner U; Heijnen L; Jimenez-Yuste V; Lee CA; Morfini M; Querol F; Roosendaal G; Santagostino E; Solimeno LP
Haemophilia; 2008 Nov; 14 Suppl 6():68-81. PubMed ID: 19134036
[TBL] [Abstract][Full Text] [Related]
9. Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice.
Manco-Johnson M
Haemophilia; 2007 Sep; 13 Suppl 2():4-9. PubMed ID: 17685917
[TBL] [Abstract][Full Text] [Related]
10. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
You CW; Lee SY; Park SK
Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
[TBL] [Abstract][Full Text] [Related]
11. Prevention of arthropathy in haemophilia: prophylaxis.
Santagostino E; Mancuso ME
Haemophilia; 2008 Nov; 14 Suppl 6():16-9. PubMed ID: 19134028
[TBL] [Abstract][Full Text] [Related]
12. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX.
Lyseng-Williamson KA; Plosker GL
Pharmacoeconomics; 2007; 25(12):1007-29. PubMed ID: 18047387
[TBL] [Abstract][Full Text] [Related]
13. Prevention of arthropathy: may it be extrapolated from patients without inhibitors to patients with inhibitors?
Hedner U
Haemophilia; 2008 Nov; 14 Suppl 6():23-7. PubMed ID: 19134030
[TBL] [Abstract][Full Text] [Related]
14. Bypassing agent prophylaxis for preventing arthropathy in patients with inhibitors.
Ewenstein BM; Wong WY; Schoppmann A
Haemophilia; 2010 Jan; 16(1):179-80. PubMed ID: 19702885
[No Abstract] [Full Text] [Related]
15. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens.
Collins PW; Björkman S; Fischer K; Blanchette V; Oh M; Schroth P; Fritsch S; Casey K; Spotts G; Ewenstein BM
J Thromb Haemost; 2010 Feb; 8(2):269-75. PubMed ID: 19943875
[TBL] [Abstract][Full Text] [Related]
16. FEIBA in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre.
Smejkal P; Brabec P; Matyskova M; Bulikova A; Slechtova M; Kissova J; Chlupova G; Muzik J; Penka M
Haemophilia; 2009 May; 15(3):743-51. PubMed ID: 19432925
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
[TBL] [Abstract][Full Text] [Related]
18. Long-term secondary prophylaxis with recombinant activated factor VII (rFVIIa) in haemophilia A with inhibitors: a case report.
Kubisz P; Plamenová I; Stasko J; Dobrotová M; Hollý P
Thromb Haemost; 2010 Apr; 103(4):868-70. PubMed ID: 20135075
[No Abstract] [Full Text] [Related]
19. Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment.
Den Uijl I; Mauser-Bunschoten EP; Roosendaal G; Schutgens R; Fischer K
Haemophilia; 2009 Nov; 15(6):1215-8. PubMed ID: 19686467
[TBL] [Abstract][Full Text] [Related]
20. Haemophilic arthropathy: the importance of the earliest haemarthroses and consequences for treatment.
Roosendaal G; Jansen NW; Schutgens R; Lafeber FP
Haemophilia; 2008 Nov; 14 Suppl 6():4-10. PubMed ID: 19134026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
